Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates Seres Therapeutics (Nasdaq: MCRB) reported fourth-quarter and full-year 2025 results and business updates on March 12, 2026. Key points: clinical data from a 15-subject investigator-sponsored SER-155 study in immune checkpoint–related enterocolitis is expected in Q2 2026, SER-603 IND-enabling work continues, and the company had $45.8M cash at year-end with runway into Q3 2026.Full-year net income from continuing operations was $5.7M, driven by lower operating expenses and installment payments from Nestle.

#MCRB Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

Trade Alert, Wednesday November 5, 2025 – Crystal Equity Research

Small-cap stocks in new downtrend, Av Dir Indx, Wed Nov 5th - #SNDL #PNRG #NNOX #MCRB #LCUT #KRNT #HEPS #CPIX #DEFT #ELTX #GSM #VYGR #BAND #ABEO #BBAI #SI #PRG #ONTF #MVO #MNTN #HPP #FPI #CABO #TIL - More: crystalequityresearch.com/trade-alert-... - #smallcap

Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates Following constructive FDA feedback, Seres is finalizing its SER-155 Phase 2 study protocol for the prevention of bloodstream infections in adults undergoing allogeneic hematopoietic stem cell transplant for the treatment of hematological malignancies Efforts are ongoing to obtain capital and other

#MCRB Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 Seres Therapeutics (Nasdaq: MCRB) will host a conference call and live audio webcast on November 5, 2025 at 8:30 a.m. ET to discuss third quarter 2025 financial results and business updates.Dial-in numbers are 800-715-9871 (domestic) or 646-307-1963 (international) using conference ID 8471287. The live webcast is available via the Investors and News section at www.serestherapeutics.com. A replay will be posted shortly after the event and archived for approximately 21 days.

#MCRB Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025

www.stocktitan.net/news/MCRB/seres-therapeu...

Seres (MCRB) Q2 Loss Narrows 34% | The Motley Fool

#MCRB #fdc26737-fdfb-42fa-b9a3-611fb7319e90 #data-news

Origin | Interest | Match

Seres Advances SER-155 Drug Pipeline as Multiple Partnership Talks Heat Up, Receives $25M Nestlé Payment Seres submits FDA protocol for SER-155 Phase 2 study while pursuing strategic partnerships. Q2 results reveal $25M Nestlé payment and pipeline expansion. See full details.

#MCRB Seres Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

Mark Your Calendar: Leading Biotherapeutics Company Seres Therapeutics Announces Q2 2025 Earnings Date Join Seres Therapeutics' Q2 earnings call on Aug 6 at 8:30 AM ET. Leading biotherapeutics firm to share latest financial performance. Get insights.

#MCRB Seres Therapeutics to Announce Second Quarter 2025 Financial Results and Business Updates on August 6, 2025

www.stocktitan.net/news/MCRB/seres-therapeu...

SmCpStr Technicals – Technical Indicators for Small-cap Stocks

Small-cap stocks with strong volume gains, Mon Jul 14th - #ISSC #WINT #VBTX #TROO #SNDL #RANI #PFIS #MCRB #IOBT #EPIX #CALC #BDRX #ACHV #ODV #KODK #KNOP - More: crystalequityresearch.com/SmCpStr/ - #smallcap

Breakthrough: Seres Therapy Cuts Deadly Infection Risk by 77% in Cancer Transplant Patients, ASCO Data Shows New ASCO data reveals SER-155's impact on immune recovery post-transplant, with significant T-cell improvements. Phase 2 trial submission planned. See full results.

#MCRB Seres Therapeutics Presents Expanded SER-155 Exploratory Biomarker Data at 2025 ASCO Annual Meeting

www.stocktitan.net/news/MCRB/seres-therapeu...

Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates Seres Therapeutics (NASDAQ: MCRB) reported Q1 2025 financial results and provided updates on its lead candidate SER-155. The company plans to submit a Phase 2 study protocol to FDA for SER-155, targeting the prevention of bloodstream infections in patients undergoing allogeneic hematopoietic stem cell transplant. Previous Phase 1b data showed a 77% relative risk reduction in bloodstream infections.Financial highlights include net income of $32.7 million for Q1 2025, compared to a net loss of $32.9 million in Q1 2024. The company had $58.8 million in cash as of March 31, 2025, with runway into Q1 2026. A $25 million payment from Nestlé is expected in July 2025. The company recently completed a 1-for-20 reverse stock split and regained Nasdaq compliance.

#MCRB Seres Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

News; ( NASDAQ: #MCRB ) Seres Therapeutics to Announce First Quarter 2025 Financial Results and Business Updates on May 7, 2025

BREAKING NEWS: ( NASDAQ: #MCRB ) MCRB announced stock split 1-20

Seres Therapeutics Breakthrough Drug Cuts Infection Risk by 77% in Stem Cell Transplants Seres' SER-155 achieves FDA Breakthrough status with promising Phase 1b data. Biotech firm strengthens financial position with reduced losses and Nestlé partnership potential.

#MCRB Seres Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

all messages are opinion | Linktree do not assume accuracy no warranty is implied no liability of any kind exists

At Seres Therapeutics #MCRB Annual Meeting on April 4, 2024, Kurt C. Graves received highest percentage of withheld votes, with approx 38% of votes against his re-election. Despite this significant level of shareholder dissent, he was re-elected.

Disclaimer
linktr.ee/disclaimer462

When Will Seres Therapeutics Reveal Its 2024 Financial Performance? Join Seres Therapeutics' conference call on March 13 at 8:30 a.m. ET to hear Q4/FY 2024 results and business updates via phone or live webcast.

#MCRB Seres Therapeutics to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide Business Updates on March 13, 2025

www.stocktitan.net/news/MCRB/seres-therapeu...

Can Seres' SER-155 Reduce Post-Transplant Infections by 77%? FDA Backs Key Trial Endpoint FDA endorses bloodstream infection reduction endpoint for SER-155 following impressive Phase 1b results. Seres plans protocol submission as it seeks development partner.

#MCRB Seres Therapeutics Receives Feedback From FDA on SER-155 Allogeneic Hematopoietic Stem Cell Transplant (allo-HSCT) Development Approach

www.stocktitan.net/news/MCRB/seres-therapeu...

Seres Therapeutics Receives $50M Payment from Nestlé, Extends Cash Runway to 2026 Seres Therapeutics secures planned $50M installment from Nestlé Health Science for VOWST business sale, with additional $25M expected in 2025, extending operations into 2026.

#MCRB Seres Therapeutics Announces Receipt of Expected $50 Million Installment Payment Related to VOWST Sale

www.stocktitan.net/news/MCRB/seres-therapeu...

Seres' SER-155 Shows Breakthrough Results in Stem Cell Transplant Study, FDA Fast-Track Follows Seres Therapeutics' SER-155 achieved significant biomarker improvements and 77% infection reduction in stem cell transplant patients, earning FDA Breakthrough status and Nestlé backing.

#MCRB Seres Therapeutics Announces New Translational Biomarker Results from SER-155 Phase 1b Clinical Study and Provides Corporate Updates

www.stocktitan.net/news/MCRB/seres-therapeu...

JUST IN: ( NASDAQ: #MCRB ) Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

#StockMarket #News

#MCRB Seres Therapeutics to Participate in Piper Sandler Healthcare Conference

www.stocktitan.net/news/MCRB/seres-therapeu...